Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
American chemical industry news
(page 3)
12 February 2026
SkyNRG Begins Construction of Delfzijl SAF Plant
The plant will produce 100,000 tonnes of SAF annually, cutting GHG emissions by up to 90%. KLM is the main off-taker. Construction starts after securing non-recourse project financing.
12 February 2026
Merck Presents New Data on Bladder and Kidney Cancer Treatments at 2026 ASCO GU Symposium
New data shows improved survival rates for bladder and kidney cancer treatments, highlighting advancements in Merck's oncology portfolio at the ASCO GU Symposium.
12 February 2026
thyssenkrupp Q1 2025/2026: Sales Down, EBIT Up, Forecast Confirmed
Order intake fell due to prior major contracts. Sales dropped 8%, but EBIT rose 10% via APEX program. Transformation progresses with strategic moves in various segments.
11 February 2026
Fluor to Expand Centrus' Uranium Enrichment Plant in Ohio
Fluor will lead engineering, procurement, and construction for Centrus' Ohio plant expansion, boosting LEU and HALEU production and creating over 1,300 jobs.
11 February 2026
INEOS Warns: Europe's Chemical Industry at Risk Without Immediate Action
Europe's chemical industry faces closures, job losses, and increased emissions. Urgent action needed on energy costs, carbon taxes, and trade defense to restore competitiveness.
11 February 2026
Merck's KEYTRUDA and KEYTRUDA QLEX Approved for PD-L1+ Platinum-Resistant Ovarian Cancer
FDA approves KEYTRUDA regimens for platinum-resistant ovarian cancer, showing reduced disease progression and death risk in trials.
How does the American chemical industry perform?
Find out with
chemXplore Analytics
Learn more
10 February 2026
ORLEN Expands LNG Operations: Increased Deliveries, Fleet, and Import Capacity
In 2025, LNG imports to Poland rose by 30%, with expanded terminal capacity and fleet. New export markets included Japan and Turkey. A second terminal will further boost capacity.
10 February 2026
FDA Grants Priority Review to Takeda's Oveporexton for Narcolepsy Type 1
Oveporexton, an orexin agonist, aims to treat narcolepsy type 1 by restoring orexin signaling. FDA's decision expected in Q3. Current treatments insufficient for many patients.
10 February 2026
bp 2025 Q4 and Full Year Results
Strong 2025 performance: $7.5bn profit, $24.5bn cash flow. Strategic divestments over $11bn. Share buyback suspended to strengthen balance sheet and invest in oil & gas opportunities.
9 February 2026
CNF's Stance on UK SAF Mandate
The SAF Mandate should exclude crop-based fuels to ensure policy integrity, investor confidence, and focus on scalable, sustainable fuel pathways for long-term emissions reduction.
9 February 2026
Symrise Antitrust Investigation Closed by U.S. DoJ
The U.S. DoJ found no unlawful practices. Symrise maintains its commitment to ethical business and anticipates similar outcomes in other investigations.
9 February 2026
Novo Nordisk Sues Hims & Hers Over Unapproved Semaglutide Products
Novo Nordisk seeks to stop Hims from selling unapproved semaglutide, citing patient safety risks and patent infringement.
9 February 2026
Lilly Acquires Orna Therapeutics for Cell Therapy Advancements
Lilly acquires Orna to enhance genetic medicine and in vivo cell engineering, focusing on autoimmune diseases with circular RNA and lipid nanoparticle technology.
9 February 2026
TotalEnergies to Supply 1 GW Solar Power to Google's Texas Data Centers
TotalEnergies signs PPAs to deliver 1 GW solar power for Google's Texas data centers, creating jobs and boosting local tax revenue. Construction starts Q2 2026.
7 February 2026
Johnson & Johnson Shares OMNY-AF Pilot Study Results at AF Symposium 2026
OMNY-AF study shows 100% procedural success, 90% effectiveness at 12 months. VARIPULSE data highlights low neurovascular events and consistent safety across clinical settings.
7 February 2026
Roche's Fenebrutinib Reduces Disability Progression in PPMS
Fenebrutinib shows 12% risk reduction in disability progression vs. OCREVUS in PPMS, with potential benefits in upper limb function and plans for regulatory submission in 2026.
6 February 2026
BASF's Engenia Herbicide Approved by EPA
EPA approves Engenia herbicide for dicamba-tolerant soybeans and cotton, offering farmers a tool against resistant weeds. BASF provides training for proper application.
6 February 2026
Covestro, Fertiglobe, TA’ZIZ Explore Ammonia Collaboration
The MoU explores ammonia supply and infrastructure, focusing on low-carbon production and long-term opportunities in China, the US, Europe, and the UAE.
6 February 2026
Ørsted Reports DKK 25.1 Billion Earnings in 2025
Ørsted strengthened its capital structure, completed divestments, and expanded offshore wind capacity, achieving a net profit of DKK 3.2 billion in 2025.
5 February 2026
Chevron Announces Leadership Changes
Chevron announces retirements and new appointments in senior leadership roles, including Corporate Business Development, Supply & Trading, and Shale & Tight divisions.
4 February 2026
LOTTE Chemical Plans 2026 Expansion in High-Performance Materials and Eco-Friendly Energy
Recorded KRW 18,483B revenue, KRW 943.6B loss in 2025. Focus on reducing commodity petrochemicals, expanding high-value materials, and boosting eco-friendly energy capacity.
4 February 2026
Novo Nordisk Launches Ozempic® Pill in US by Q2 2026
FDA approves Ozempic® tablets for type 2 diabetes, offering enhanced bioavailability. Launch set for Q2 2026.
4 February 2026
Lilly Q4 2025 Financial Results and 2026 Outlook
Q4 revenue rose 43% to $19.3B, EPS up 51%. FDA approved Kwikpen, expanded Jaypirca use. 2026 revenue guidance: $80B-$83B, EPS: $33.50-$35.00.
4 February 2026
ARLANXEO Opens New HNBR Plant in China
The new plant in Changzhou boosts HNBR production for strategic sectors, enhances local R&D, and supports sustainability with advanced technology and energy efficiency.
4 February 2026
UPM 2025 Financials: Strong Cash Flow, Strategic Moves
Q4 sales and EBIT down, but cash flow strong. Strategic actions include joint ventures, investments, and closures. Sustainability recognized with top ratings.
3 February 2026
Novo Nordisk Reports 6% Sales Growth in DKK, 10% at CER for 2025
Operating profit fell 1% in DKK, rose 6% at CER. US FDA approved oral GLP-1 for obesity. 2026 sales growth expected to decline due to pricing and competition. New treatments in pipeline.
3 February 2026
Novo Nordisk 2025 Financial Report
Sales rose 10% at CER, operating profit up 6%. US FDA approved oral GLP-1. 2026 outlook: sales/profit growth -5% to -13% at CER. New share repurchase program announced.
3 February 2026
SABIC Introduces Biocompatible Materials and Fluoropolymer Alternatives at MD&M West
Showcasing medical-grade thermoplastics, SABIC addresses performance and regulatory challenges, offering solutions for drug delivery, patient testing, and surgical applications.
3 February 2026
Merck Announces Q4 and Full-Year 2025 Financial Results, Highlights Pipeline Progress
Strong oncology and animal health sales, positive trial results, and strategic acquisitions drive growth. 2026 outlook projects sales up to $67B, with EPS impacted by acquisition charges.
3 February 2026
Elkem's MIRASIL™ N‑DML 15 Wins SEAL Environmental Initiative Award
MIRASIL™ N‑DML 15, a sustainable silicone blend, offers high performance with reduced carbon footprint, using renewable sunflower-based carrier, enhancing Elkem's eco-friendly product line.
← Previous
Next →
